Citius pharmaceuticals completes merger of subsidiary with tenx keane to form citius oncology, inc.

Lymphir™ for the treatment of cutaneous t-cell lymphoma approved by the fda citius pharmaceuticals, inc. holds approximately 90% of publicly traded citius oncology, inc. shares of citius oncology, inc. anticipated to begin trading on nasdaq under the ticker "ctor" on august 13, 2024 cranford, n.j., aug. 12, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius pharma" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has completed the previously announced merger of its oncology subsidiary with tenx keane acquisition ("tenx") (nasdaq: tenk), a publicly traded special purpose acquisition company.
CTXR Ratings Summary
CTXR Quant Ranking